Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Stockholders' Equity (Details Textual)

v3.23.1
Note 8 - Stockholders' Equity (Details Textual) - USD ($)
 3 Months Ended 12 Months Ended
Feb. 03, 2023
Jan. 30, 2023
Jan. 27, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)       $ 1.32   $ 3.30  
Invagen Pharmaceuticals Inc [Member]              
Contingent Fee, Percentage of Proceeds of Future Financings 7.50%            
Contingent Fee, Maximum Allowable Amount $ 4,000,000.0            
Payment of Contingent Fee $ 200,000            
Prefunded Warrant [Member]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)     1,492,299        
Class of Warrants or Rights, Price Less Than Stock Issuance Price (in dollars per share)     $ 0.001        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)     $ 0.001        
January 2023 Warrants [Member]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)     1,940,299        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)     $ 1.55        
Proceeds from Issuance or Sale of Equity     $ 240,000        
Class of Warrants or Rights, Offering Price (in dollars per share)     $ 0.125        
Warrants and Rights Outstanding, Term (Year)     3 years        
Securities Purchase Agreement [Member]              
Stock Issued During Period, Shares, New Issues (in shares)     448,000        
Shares Issued, Price Per Share (in dollars per share)     $ 1.55        
Proceeds from Issuance or Sale of Equity     $ 3,000,000.0        
Restricted Stock Units (RSUs) [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)       $ 12.17      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)       13,137   13,137  
Share-Based Payment Arrangement, Expense       $ 11,000 $ 569,000    
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount       $ 100,000      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 8 months 15 days      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)           3,333  
Two Thousand Fifteen Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)   5,266,666         266,666
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   10 years          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       5,122,489